Search for Clinical Trial Results

Sponsored By

Pyoderma - 18 Studies Found

Status Study
Withdrawn Study Name: Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2008-06-02
Interventions: Drug: adalimumab 40 mg weekly adalimumab injection.
Completed Study Name: Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Condition:
  • Pyoderma Gangrenosum
  • Crohn's Disease
  • Diabetic Foot
  • Varicose Ulcer
  • Pressure Ulcer
  • Date: 2014-10-29
    Interventions: Other: Usual care advanced dressings, off-loading, venous ulcer compression, arterial screening
Completed Study Name: Spesolimab in Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2025-11-04
Interventions: 900 mg of spesolimab intravenously (IV) administered at Weeks 0, 3, 6, 9, 12 and 15.
Completed Study Name: Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Condition: Pyoderma Gangrenosum
Date: 2025-11-04
Interventions: Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.
NOT_YET_RECRUITING Study Name: Deucravacitinib in PG
Condition: Pyoderma Gangrenosum
Date: 2025-11-04
Interventions: 6 mg tablet
Completed Study Name: Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2025-11-04
Interventions: vilobelimab infusion
<<< Previous